- Home
- LYEL
as 07-26-2024 4:00pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 706.2M | IPO Year: | 2021 |
| Target Price: | $4.00 | AVG Volume (30 days): | 827.6K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.18 - $3.26 | Next Earning Date: | 08-06-2024 |
| Revenue: | $68,000 | Revenue Growth: | -99.92% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Lyell Immunopharma Inc. News
LYEL Breaking Stock News: Dive into LYEL Ticker-Specific Updates for Smart Investing
Benzinga
a month ago
Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
GlobeNewswire
a month ago
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
GlobeNewswire
2 months ago
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
GlobeNewswire
3 months ago
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
Simply Wall St.
3 months ago
Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
MT Newswires
3 months ago
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows
Associated Press Finance
3 months ago
Lyell Immunopharma: Q1 Earnings Snapshot
GlobeNewswire
3 months ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Compare LYEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.